Business Context and Reporting Period
This Form 8-K, dated January 17, 2023, reports that Leap Therapeutics, Inc. (Leap) completed the acquisition of Flame Biosciences, Inc. (Flame) on the same date. The transaction was structured as a tax-free reorganization where Flame became a wholly-owned subsidiary of Leap. Leap is an emerging growth company incorporated in Delaware with its principal offices in Cambridge, MA.
Key Financial Metrics and Transaction Terms
The filing details the consideration paid for the acquisition but does not provide historical revenue, profit, or cash flow metrics for either entity within this specific document.
- Equity Consideration: Leap agreed to issue approximately 19,794,373 shares of Common Stock and approximately 136,833 shares of Series X Non-Voting Convertible Preferred Stock to Flame stockholders.
- Preferred Stock Terms: Each share of Series X Preferred Stock is convertible into 1,000 shares of Common Stock. Approximately 15,662 shares were held back as "Holdback Shares" for potential indemnification claims.
- Contingent Consideration: Leap may pay 80% of after-tax net proceeds if Flame's FL-101 or FL-103 program assets are sold post-closing.
- Price Adjustment: Additional shares may be issued if Flame's actual net cash at closing exceeds estimates.
- Debt and Liquidity: The filing text does not provide specific values for current debt, cash balances, or liquidity positions.
Material Changes and Corporate Actions
The primary material change is the consolidation of Flame's operations into Leap. Specific corporate actions include:
- Board Appointments: Patricia Martin and Christian Richard were appointed to Leap's Board of Directors effective immediately after the merger.
- Stockholder Approval Required: Leap must hold a special meeting to approve the conversion of Series X Preferred Stock into Common Stock to comply with Nasdaq listing rules. If not approved within 90 days, Leap must seek approval at least every six months thereafter.
- Warrant Conversion: Outstanding Flame warrants were assumed by Leap and converted into warrants for Leap Common Stock and Series X Preferred Stock.
- Option Cancellation: All unexercised Flame stock options were cancelled without payment.
Guidance, Outlook, and Risks
Management commentary is limited to forward-looking statements regarding the integration of operations and the sufficiency of cash resources to fund combined operations. The filing explicitly warns that financial statements and pro forma information will be filed in an amendment within 71 days.
Key Risks and Contingencies:
- Stockholder Approval: Failure to obtain timely approval for the conversion of Series X Preferred Stock could result in cash settlement obligations or listing delisting risks.
- Integration: Risks associated with successfully integrating Flame's operations and realizing anticipated cost savings.
- Clinical Development: Uncertainty regarding the advancement, safety, efficacy, and regulatory approval of product candidates (including FL-101 and FL-103).
- Liquidity: Risk that combined cash resources may be insufficient to fund operations and liabilities incurred from the merger.
Investor Verification Checklist
- Verify the outcome of the special stockholder meeting regarding the conversion of Series X Preferred Stock.
- Review the upcoming amendment to this 8-K (due within 71 days) for Flame's historical financial statements and pro forma combined financial information.
- Monitor the status of the registration statement for the unregistered securities issued in the merger, which Leap agreed to file within 75 days.
- Assess the impact of the 15,662 Holdback Shares on the final equity distribution to Flame stockholders.
- Confirm the sufficiency of Leap's cash runway post-acquisition as detailed in future filings.